Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (368)	12/2/2002 2:40:39 PM
From: scaram(o)uche	Respond to of 598

Sounds just like Tularik to me. There are at least three advanced projects for metabolic diseases. I just believe that they don't want it known, which molecule just entered clinical testing. But they do want it known that they hit the "2-3 INDs for 2002" objective, set in January. This is exactly the way I like it. Obesity, lipids, diabetes...... the markets are huge. Even within lipid disorders, I couldn't make a guess at which of two targets might be furthest along. IMO, they're just forcing competitors to spend money and time to get a feel for the project.